MindMaze Therapeutics Holding (XSWX:MMTX) EV-to-EBITDA: (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:MMTX MindMaze Therapeutics Holding SA XSWX:MMTX
4 GF Score
Price CHF0.16
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MindMaze Therapeutics Holding's enterprise value is CHF17.23 Mil. MindMaze Therapeutics Holding does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate MindMaze Therapeutics Holding's EV-to-EBITDA at this moment.

The historical rank and industry rank for MindMaze Therapeutics Holding's EV-to-EBITDA or its related term are showing as below:

XSWX:MMTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.22   Med: 0   Max: 0
Current: -2.15
XSWX:MMTX's EV-to-EBITDA is ranked worse than
100% of 402 companies
in the Biotechnology industry
Industry Median: 12.2 vs XSWX:MMTX: -2.15

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2026-07-25), MindMaze Therapeutics Holding's stock price is CHF0.158. MindMaze Therapeutics Holding does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate MindMaze Therapeutics Holding's PE Ratio (TTM) at this moment.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).

MindMaze Therapeutics Holding  (XSWX:MMTX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

MindMaze Therapeutics Holding's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.158/
=

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

MindMaze Therapeutics Holding EV-to-EBITDA Related Terms

MindMaze Therapeutics Holding EV-to-EBITDA Historical Data

* Premium members only.

The historical data trend for MindMaze Therapeutics Holding's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindMaze Therapeutics Holding EV-to-EBITDA Chart

MindMaze Therapeutics Holding Annual Data
Trend Dec24 Dec25
EV-to-EBITDA
0.00 -35.28

MindMaze Therapeutics Holding Semi-Annual Data
Dec24 Dec25
EV-to-EBITDA 0.00 0.00

XSWX:MMTX vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison

For the Biotechnology subindustry, MindMaze Therapeutics Holding's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindMaze Therapeutics Holding EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MindMaze Therapeutics Holding's EV-to-EBITDA falls into.


XSWX:MMTX
4GF Score
MindMaze Therapeutics Holding SA XSWX:MMTX
EV-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding EV-to-EBITDA Calculation

MindMaze Therapeutics Holding's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=17.234/
=

MindMaze Therapeutics Holding Business Description

Other Exchanges RLFTY:USAMMTXz:UK
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
4GF Score

Get the complete analysis for XSWX:MMTX

EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF0.16
Price